ADELAIDE — South Australian drivers are being urged to use real-time fuel price apps to save money at the bowser after a statewide compliance blitz saw nearly $20,000 in fines issued to petrol stations for inaccurate pricing, the state government announced this week.

The reminder comes as the full fuel excise returned to its usual level on July 1, adding further pressure to household budgets and making it increasingly important for motorists to compare prices before filling up. Since conflict in the Middle East began earlier this year, inspectors from Consumer and Business Services have carried out more than 1,000 fuel price inspections across metropolitan and regional South Australia to ensure petrol stations are complying with the state’s real-time fuel pricing laws.

The inspections have resulted in 29 expiation notices being issued to service stations, with nearly $20,000 in fines handed out for failing to correctly report fuel prices or list fuel as unavailable when it was not. A further 24 warning letters have also been issued to retailers found to be non-compliant during the ongoing enforcement effort.

Under South Australia’s real-time fuel pricing scheme, retailers are required to update a central database within 30 minutes whenever prices change or fuel becomes unavailable at the pump. That information is then made publicly available through a range of free fuel price comparison apps, allowing motorists to check prices across nearby service stations before deciding where to fill up.

Consumer and Business Affairs Minister Michael Brown said the timing of the reminder was particularly important given the return of the full fuel excise. “With the fuel excise now back at its usual level, make sure you are getting the best priced fuel by using the fuel watch apps,” Brown said. He added that the government remains committed to holding non-compliant retailers accountable. “The Malinauskas Government is cracking down on petrol stations who fail to comply with our real-time petrol price monitoring and South Australians can save more than $100 a year on fuel through our Fuel Watch initiative.”

Wednesday’s update builds on a series of earlier enforcement actions the state government has taken throughout 2026 as part of its broader crackdown on fuel pricing compliance. An April compliance blitz saw more than 500 inspections carried out across the state, resulting in nine service stations fined nearly $8,000 at the time, with a further 11 sites placed under investigation. Those fined in that earlier round included stations across both regional and metropolitan areas, among them Coober Pedy, Bordertown, Strathalbyn, Renmark, Berri, Karoonda, Goodwood and Park Holme. At the time, Brown said the government was taking a “zero-tolerance approach” to non-compliance, adding that the government intended to “name and shame those who fail to meet their obligations.”

A separate compliance blitz conducted ahead of a long weekend in early June saw more than 200 additional inspections carried out across Adelaide, the West Coast, Eyre Peninsula, Yorke Peninsula, the Riverland and the Limestone Coast. Cumulatively, since the Middle East conflict began earlier this year, Consumer and Business Services has investigated nearly 400 complaints and conducted around 800 service station inspections, resulting in 22 fines totaling more than $12,000 and 18 written warnings, according to figures the government released in early June, ahead of the more recent enforcement figures announced this week.

To strengthen its enforcement capabilities, the South Australian government has passed new legislation significantly increasing penalties for non-compliant fuel retailers. The Fair Trading (Fuel Pricing Information Penalties) Amendment Bill became the first law to pass through the state’s Parliament this session, with the changes set to take effect later this month. Under the new penalty structure, on-the-spot expiation fines for breaches will jump from $550 to $5,000 per offense, while the maximum penalty a court can impose will double from $10,000 to $20,000. Premier Peter Malinauskas said at the time the legislation passed that petrol stations failing to comply “will face the consequences,” which now include penalties of up to $20,000 per offense.

The government has also committed additional resources to enforcement, funding an extra 100 inspections per month as part of a $1.2 million election commitment, with recruitment currently underway for additional Consumer and Business Services inspectors to expand the program’s reach across the state. Brown reiterated that the increased enforcement reflects a campaign promise made ahead of the government’s election. “The government is delivering on our election commitment to make sure petrol stations do the right thing by South Australian motorists with higher penalties and more inspections across the state,” Brown said.

According to the Royal Automobile Association of South Australia, motorists who consistently use real-time fuel pricing apps to compare prices before filling up can save an average of $117 a year based on typical fuel consumption patterns. Extrapolated across the broader South Australian driving population, those individual savings are estimated to total approximately $58 million annually if more drivers made consistent use of the available pricing tools.

Drivers looking to take advantage of the real-time pricing scheme can compare fuel prices using a range of free apps, including the RAA app, which provides both pricing and availability information, along with Petrol Spy, Motor Mouth, SA Bowser: Should I Fuel? and ServoTrack, all of which are available for download through the App Store or Google Play.

With the fuel excise back at its full rate and global oil prices remaining volatile amid ongoing tensions in the Middle East, South Australian officials have continued to emphasize that accurate, real-time price reporting plays a critical role in helping motorists manage rising transportation costs. As the state’s compliance program continues to expand, with tougher penalties set to take effect later this month, officials say they expect the threat of significantly higher fines to further deter non-compliant behavior among the state’s fuel retailers, while consumer advocates continue to encourage drivers to make regular use of the available comparison tools to secure the best possible prices at the pump.

Speaking at a NATO summit in Turkey, Trump said he had no interest in further talks with Iran and warned that Washington would likely carry ‌out additional strikes on ⁠Wednesday ⁠night.

Trump’s comments marked the latest setback in the back-and-forth talks that have swung between threats of escalation and hopes for diplomacy, leaving investors wrong-footed by several ​false starts toward a peace deal.

“Duration is the key here. How long does this go on?” said Rob Haworth, senior investment strategist ​at U.S. Bank Wealth Management in Seattle. “If we see damage to Iranian infrastructure, the market may have to respond more seriously to that because there’s likely Iranian retaliation.” AI heavyweights Microsoft, Amazon and Alphabet each fell, weighing on the S&P 500. Broadcom gained ​after Apple said it plans to spend more than $30 billion as part of ⁠a chip-supply ‌agreement reached earlier this week with the chipmaker.

“Any time you get an announcement from Apple about ​using your equipment, it’s ​pretty positive — especially when you have 2.5 billion Apple devices in people’s hands around the ⁠globe,” said Art Hogan, chief market strategist at B. Riley Wealth. Nvidia rose after ​the Information reported that China plans to allow its top AI firms to buy ​a limited number of the company’s H200 chips.

Live Events

According to preliminary data, the S&P 500 lost 22.57 points, or 0.30%, to end at 7,481.28 points, while the Nasdaq Composite gained 52.52 points, or 0.19%, to 25,868.29. The Dow Jones Industrial Average fell 592.43 points, or 1.12%, to 52,332.72.
Oil prices jumped following Trump’s remarks, with Brent crude futures settling up 5.2%. Treasury yields also rose as the selloff spread to bonds.The latest escalation in the conflict threatened to unsettle the equities rally that has ‌carried the benchmark S&P 500 up about 9% so far this year, despite sharp declines after the Mideast war started.

A renewed jump in oil prices could revive inflation concerns and further complicate the ​Federal Reserve’s path. Energy ​price-sensitive travel stocks fell as ⁠higher oil prices stoked concerns over fuel costs and demand. United Airlines and Delta Air Lines both lost ground.

Cruise operators also slipped, with Carnival and Norwegian Cruise Line both down.

The International Monetary Fund on Wednesday once again lowered its 2026 global growth ​forecast to 3%, warning of ongoing risks posed by the war in the Middle East.

Inflation worries mounted at the U.S. central bank’s meeting last month, as officials followed Federal Reserve Chairman Kevin Warsh’s lead to a more stripped-down policy statement, minutes of the session showed on Wednesday.

Traders project a likely rate hike by the Fed’s December meeting, according to CME’s Fedwatch.

For executives and frequent business travelers, transportation is more than a way to get from one location to another. It is an important part of the overall travel experience that influences productivity, comfort, and professionalism.

In major business destinations such as Boston and Los Angeles, premium transportation services help travelers navigate busy schedules while maintaining a high standard of service.

Whether arriving at Boston Logan International Airport for a corporate conference or attending executive meetings across Southern California, reliable chauffeur-driven transportation can make business travel significantly more efficient. Professional airport transfers and executive car services provide the consistency and convenience that modern professionals require.

Why Luxury Transportation Matters for Business Travel

Corporate travelers often face demanding itineraries that include airport transfers, client meetings, networking events, and multiple appointments throughout the day. Transportation delays or unreliable service can create unnecessary stress and disrupt carefully planned schedules.

Luxury transportation services address these challenges by offering experienced chauffeurs, executive-class vehicles, and dependable scheduling. Rather than worrying about navigation, parking, or transportation availability, travelers can focus entirely on their professional responsibilities.

For organizations hosting clients or visiting executives, premium transportation also reinforces a positive and professional brand image.

Boston Airport Car Service for Executive Arrivals

Boston remains one of America’s leading centers for finance, healthcare, education, technology, and biotechnology. Thousands of executives travel through Boston Logan International Airport every year to attend meetings, conferences, and industry events.

A professional Boston airport car service provides seamless transportation between the airport, hotels, business districts, and corporate offices. Pre-arranged transportation helps eliminate uncertainty while ensuring timely arrivals and departures.

Many business travelers choose Detailed Drivers Boston because executive transportation requires reliability, professionalism, and attention to detail. Experienced chauffeurs understand local traffic patterns and can help travelers move efficiently throughout the city.

For visitors unfamiliar with Boston, premium airport transportation offers both convenience and peace of mind.

LA Chauffeur Service for Corporate Mobility

Los Angeles presents unique transportation challenges due to its size, traffic conditions, and diverse business districts. Executives frequently travel between airports, production studios, technology hubs, corporate headquarters, and event venues located throughout the region.

A professional LA chauffeur service provides a practical solution for managing these travel demands. Dedicated chauffeurs allow executives to remain productive while traveling, turning commute time into valuable working time.

Many organizations trust Detailed Drivers Los Angeles because professional transportation providers understand the expectations of executive travelers. From punctual pickups to personalized service, chauffeur-driven transportation supports both efficiency and comfort.

For executives meeting clients or attending important corporate functions, luxury transportation also contributes to a polished and professional appearance.

Key Benefits of Premium Chauffeur Services

Greater Productivity

Travelers can focus on emails, presentations, conference calls, and meeting preparation while in transit.

Reliable Scheduling

Professional transportation services prioritize punctuality and efficient route planning.

Comfort and Privacy

Executive vehicles provide a comfortable environment suitable for confidential conversations and focused work.

Enhanced Corporate Image

Premium transportation creates a strong impression during client visits and executive engagements.

Planning Transportation for Multi-City Business Travel

As business travel becomes increasingly interconnected, many executives travel between multiple cities during a single trip. Coordinating reliable transportation in each destination can improve efficiency and reduce travel-related stress.

Professionals researching regional travel solutions may also find resources such as best NYC to boston car services useful when comparing transportation options for business travel between major metropolitan markets.

Evaluating transportation solutions in advance helps organizations create more effective travel strategies.

Choosing the Right Transportation Partner

When selecting a transportation provider, business travelers should consider factors such as reliability, chauffeur experience, fleet quality, customer support, and scheduling flexibility. Providers that specialize in executive transportation are often best equipped to meet the expectations of corporate clients.

A trusted transportation partner can become an important extension of a company’s broader travel management strategy.

Conclusion

Luxury transportation plays a vital role in successful business travel. Whether utilizing a Boston airport car service for efficient airport transfers or arranging an LA chauffeur service for executive mobility throughout Southern California, professionals benefit from transportation solutions designed around reliability, comfort, and professionalism.

By incorporating premium transportation into their travel plans, executives can improve productivity, maintain schedules, and create a seamless experience from arrival to departure.

Shares of International Business Machines Corp. fell more than 1.6 percent Tuesday, closing at $301.10 as broader technology sector pressures and profit-taking weighed on the stock amid ongoing debates about artificial intelligence investment returns and enterprise spending trends.

The decline of $5.03 per share marked a modest pullback for the blue-chip technology company, which has navigated a complex environment of AI opportunities, legacy system modernization challenges and macroeconomic uncertainty. IBM’s performance reflected mixed investor sentiment across the sector, where enthusiasm for generative AI capabilities has at times clashed with questions over near-term monetization and competitive dynamics.

IBM has positioned itself as a leader in hybrid cloud, enterprise AI through its Watsonx platform and quantum computing initiatives. Recent announcements highlighted continued innovation, including new compact z17 and LinuxONE systems designed to address data center space and cost constraints, as well as advancements in quantum research collaborations.

Despite these developments, the stock faced headwinds Tuesday. Market participants cited broader rotation away from some technology names, valuation concerns in the AI space and sector-wide caution following recent volatility in chipmakers and software providers. IBM’s shares have experienced periods of strength tied to its software and infrastructure growth but remain sensitive to shifts in enterprise IT spending.

Analysts have pointed to IBM’s stable business model, anchored by recurring revenue from software, consulting and infrastructure, as a source of resilience. The company’s focus on mission-critical systems for large enterprises provides a moat, though emerging AI tools capable of accelerating legacy code modernization have raised questions about long-term demand for certain services.

IBM’s latest financial performance showed solid execution in key areas. Software and infrastructure segments have delivered growth, supported by hybrid cloud adoption and AI-related offerings. However, some observers noted moderating momentum in parts of the business amid competitive pressures and cautious client spending in an uncertain economic backdrop.

The company’s dividend remains attractive to income-focused investors, contributing to its appeal as a defensive technology play. With a consistent payout history, IBM continues to draw long-term holders even as growth-oriented investors debate its positioning relative to pure-play AI companies.

Tuesday’s trading volume was in line with recent averages, suggesting the move was part of normal market mechanics rather than a reaction to company-specific news. IBM shares have traded within a 52-week range that reflects both optimism around its strategic initiatives and periodic concerns over execution and competition.

Broader market context played a role. Technology stocks showed uneven performance as investors assessed the sustainability of AI-related capital expenditures. While leaders in semiconductors and cloud computing posted mixed results, concerns about high valuations and return timelines rippled through the sector.

IBM has responded to the evolving landscape with significant investments in emerging technologies. Its commitment to quantum computing, including partnerships with national laboratories and healthcare organizations, aims to establish leadership in a field with potential long-term transformative impact. Recent milestones include computations related to fusion materials, underscoring progress in practical applications.

Enterprise clients continue to prioritize modernization of critical infrastructure, where IBM’s expertise in secure, reliable systems provides differentiation. The company’s Red Hat acquisition has strengthened its hybrid cloud capabilities, enabling organizations to balance on-premises and public cloud environments while addressing security and compliance needs.

Challenges persist in the consulting and services segments, where AI tools promise to automate tasks traditionally handled by human experts. IBM is adapting by integrating AI across its offerings, but the pace of disruption remains a focal point for investors evaluating future growth trajectories.

Wall Street analysts maintain a range of views on IBM. Some highlight its valuation as reasonable given stable cash flows and dividend yield, while others call for clearer evidence of AI-driven acceleration in revenue and margins. Consensus price targets reflect a mix of optimism and measured expectations.

Looking forward, IBM’s upcoming earnings and strategic updates will be closely watched. Investors seek signs of sustained momentum in high-margin software, successful integration of AI capabilities and progress on quantum and infrastructure innovations. Macroeconomic factors, including interest rates and corporate budgets, will also influence performance.

The session’s decline comes after periods of strength for IBM, during which the stock benefited from its reputation for reliability amid broader market volatility. As one of the original members of the Dow Jones Industrial Average, IBM often serves as a proxy for mature technology leadership in an industry dominated by younger, high-growth names.

Market strategists note that rotations between growth and value stocks can create short-term pressure on established players like IBM even when fundamentals remain sound. The company’s diversified revenue streams provide a buffer compared with more concentrated peers.

In the competitive landscape, IBM continues to face pressure from hyperscale cloud providers and specialized AI firms. However, its emphasis on enterprise-grade solutions, security and regulatory compliance positions it favorably for clients in finance, healthcare and government sectors where trust and reliability are paramount.

Tuesday’s close leaves IBM shares in a consolidation phase within their yearly range. Technical indicators suggest potential support levels near recent lows, with resistance tied to prior highs achieved during periods of positive sentiment around AI and cloud initiatives.

As the technology sector navigates the intersection of innovation and valuation realities, IBM’s path reflects the broader challenges and opportunities facing established technology giants. Its ability to translate research breakthroughs and strategic investments into consistent growth will determine whether it can outperform in an increasingly AI-centric market.

Honda is recalling more than 325,000 vehicles over faulty rearview image displays, which could increase the risk of a crash, according to federal regulators.

The recall affects 2018-2020 Odyssey vehicles, the National Highway Traffic Safety Administration (NHTSA) announced on Wednesday.

A total of 325,588 vehicles are covered by the recall effort.

HONDA RECALLS MORE THAN 880,000 VEHICLES OVER REAR SUSPENSION FAILURE RISK

Honda is recalling more than 325,000 vehicles over faulty rearview image displays. (Honda / Fox News)

The NHTSA said the recall was issued due to rearview cameras that may not display properly.

“Water may enter into the rearview camera, which can cause the rearview camera image to fail to display when the vehicle is in reverse,” the recall notice reads.

A display malfunction could increase the risk of a crash, the NHTSA said.

The recall affects 2018-2020 Odyssey vehicles. (Scott Olson/Getty Images / Getty Images)

The announcement expands a previous recall, which affected certain 2019-2020 Honda Odyssey vehicles.

Owners affected by the recall may take their cars to Honda dealers, so the rearview camera can be replaced free of charge, according to the NHTSA.

Owner notification letters are expected to be mailed on Aug. 24.

HONDA RECALLS 99,000 VEHICLES OVER FLAW THAT COULD TRIGGER UNINTENDED AIRBAG DEPLOYMENT

A total of 325,588 vehicles are covered by the recall effort. (Justin Sullivan/Getty Images / Getty Images)

GET FOX BUSINESS ON THE GO BY CLICKING HERE

This comes after Honda issued two separate recalls in recent months that included other car models.

This included more than 880,000 vehicles being recalled because a key rear suspension part can rust and fail, and nearly 99,000 cars that were recalled over a defect that could cause airbags to deploy unexpectedly during a crash.

Jean Bennett and Albert Maguire are married. They are also the reason several hundred people who were going blind have retained their sight.

Their lab at the University of Pennsylvania spent the better part of the 1990s working out the technical details of a gene therapy for Leber congenital amaurosis — a genetic disease that strips away retinal function in childhood, usually ending in total blindness before adulthood. They tried it first in dogs. A group of Swedish Briard puppies, born with the same genetic defect, had their sight restored. Bennett and Maguire adopted them.

In 2007, Maguire administered the first injection into a human patient — a 26-year-old woman at Children’s Hospital of Philadelphia. A decade later, in December 2017, the FDA approved Luxturna: the first gene replacement therapy for an inherited disease in US history. At the April 2026 Breakthrough Prize ceremony in Los Angeles, Bennett, Maguire, and their longtime collaborator Katherine High shared the Breakthrough Prize in Life Sciences for that work. Some of the patients who received Luxturna have since qualified for driver’s licenses.

What the Disease Does, and What the Therapy Fixes

Leber congenital amaurosis is caused by a mutation in the RPE65 gene, which produces a protein the retina needs to complete its visual cycle — the process by which light hitting the eye becomes an electrical signal sent to the brain. Without functional RPE65, that cycle breaks. The retina can still receive light but cannot convert it into anything the brain can read. Patients lose light sensitivity progressively, typically experiencing severe vision loss before 18 and total blindness shortly after.

The therapy developed by Bennett, High, and Maguire uses a modified adeno-associated virus — a delivery vehicle that can carry genetic material without triggering immune rejection — to insert a working copy of the RPE65 gene directly into retinal cells via subretinal injection. One treatment per eye, administered days apart. The corrected cells begin producing the protein, the visual cycle resumes, and patients who could previously see only in very bright light start perceiving details they had never been able to make out.

Patients in early clinical trials described seeing snow for the first time. One described seeing the moon. Another saw stars. The disease affects an estimated 1,000 to 3,000 people in the United States — a population small enough that commercial development alone would never have funded the three decades of research required to reach them. Katherine High, who served as the founding director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics at CHOP and is now CEO of RhyGaze, a gene therapy company based in Philadelphia and Switzerland, helped bridge the gap between academic science and the regulatory pathway that eventually made Luxturna approvable. Bennett, 71, and Maguire, 66, remain emeritus professors at Penn. The therapy they built together has been approved not just by the FDA but by regulators in Europe, where Novartis licensed it for distribution outside the US.

Why Forty Years Is the Point

Bennett joined Penn’s faculty in 1992. The first human clinical trial ran in 2007. FDA approval came in 2017. The prize arrived in 2026. That timeline — three-plus decades from academic lab to pharmacy — accurately describes how foundational biomedical research moves when it is not being chased by a commercial deadline.

This is the argument Yuri Milner has made consistently in designing the Breakthrough Prize. Most private funding in science rewards proximity to an application. Grants chase outcomes. Venture capital chases returns on timescales measured in years, not decades. The researchers who spend thirty years on a disease affecting fewer than 3,000 Americans are working outside the incentive structures that normally sustain scientific careers. They are building a cathedral, in Milner’s phrase from the 2026 prize announcement — “on foundations laid down by the giants who came before them..”

The Prize was designed to recognize exactly that kind of researcher: contributors whose work is foundational rather than immediately monetizable, operating on timescales that most institutional funding structures struggle to sustain. Milner’s own training as a theoretical physicist shaped the conviction directly. He spent years in a discipline where the gap between discovery and application is routinely measured in generations — where the mathematics developed in one century becomes the engineering of the next.

What the Prize adds to recognition is visibility. A $3 million award, handed out on a Hollywood stage in front of an audience that includes the CEOs of Nvidia and OpenAI alongside film and music performers, reaches a different public than a journal publication or a tenure committee commendation. That visibility matters because public understanding of what science produces determines, over time, what science gets funded.

The 2026 Life Sciences Class, Taken Together

Bennett, High, and Maguire shared the ceremony with two other Life Sciences prizes that, read alongside theirs, trace a consistent pattern in how Milner and the Breakthrough Prize Foundation think about which research deserves recognition.

Stuart Orkin and Swee Lay Thein received a prize for decades of work that eventually led to gene-editing treatments for sickle cell disease and beta-thalassemia — two inherited blood disorders that together affect millions of people globally, with the heaviest burden falling on populations in sub-Saharan Africa, South Asia, and the Mediterranean. Thein identified a genetic region linked to elevated fetal hemoglobin production in adults, a trait that naturally softens the severity of both conditions. Orkin identified BCL11A, the specific gene that suppresses fetal hemoglobin after birth. Their combined findings gave researchers a precise molecular target: silence BCL11A, allow protective fetal hemoglobin to persist, and the disease becomes dramatically more manageable. Gene-editing therapies built on exactly that logic have since reached patients and received regulatory approval.

Rosa Rademakers and Bryan Traynor were recognized for identifying the C9orf72 gene mutation as the most common known genetic cause of both ALS and frontotemporal dementia — two conditions that had long resisted genetic explanation and had largely been treated as separate diseases. The discovery that a single mutation could drive both redirected an entire research field toward a testable, actionable target. Clinical trials targeting C9orf72 are now running.

Each of the three prizes honored research that required patience measured in decades, produced results that could not have been commercially predicted at the outset, and has since moved from academic publication toward patients who had no other options.

What the Eureka Manifesto Said About Biology

In his Eureka Manifesto, Milner identified life sciences as one of the deepest mismatches in all of science — research that is profound in its importance to human welfare and chronically underfunded relative to that importance. The book makes the case that directing serious capital toward fundamental biological research is one of the highest-return investments a civilization can make, precisely because the downstream benefits cannot be predicted from the research itself at the time it is being done.

Luxturna illustrates this directly. Bennett’s early work in the 1990s was about understanding how a specific protein interacts with the retina. It was a basic science question about a poorly understood mechanism. It became a therapy because the science pointed there, because the researchers followed it long enough, and because the clinical and regulatory infrastructure existed to translate the findings. The Giving Pledge commitment Milner made alongside his wife Julia in 2012 formalized this philosophy at the level of personal wealth: invest in scientists, not just projects. Trust the researchers building foundations before the applications are visible.

That framing has practical consequences for how the Prize is structured. It does not restrict its recognition to research that has already produced a commercial product. It recognizes the discovery, the mechanism, the molecular target — the work that makes products possible years or decades later. The 2026 Life Sciences class is evidence that this distinction is not semantic. All three prize-winning programs produced fundamental knowledge long before they produced clinical outcomes.

The Cathedral and the Patient

At the 2026 ceremony, Anne Hathaway and Alex Honnold presented a video about Baby KJ — KJ Muldoon, a child born with carbamoyl phosphate synthetase 1 deficiency, a rare metabolic disease in which the liver cannot process ammonia properly. Without treatment, the ammonia buildup becomes toxic to the brain. KJ was only days old when he was diagnosed and spent his first ten months at the hospital. His doctors at Children’s Hospital of Philadelphia developed a personalized CRISPR-based gene therapy using base-editing techniques pioneered by previous Breakthrough Prize laureate David Liu — a one-time treatment designed specifically around KJ’s individual mutation. He has since been walking, talking, and meeting developmental milestones that were once uncertain.

The connection between KJ’s treatment and the research honored at the same ceremony runs through the logic of the entire evening. Liu’s base-editing work, recognized by a prior Breakthrough Prize, made KJ’s therapy possible. Bennett, High, and Maguire’s gene therapy work, recognized this year, established the delivery mechanisms and regulatory precedents that personalized gene therapies now build on. The cathedral metaphor Milner used in his statement holds: each laureate’s work is a section of a structure that no single researcher could complete alone, and whose full dimensions no single generation could see.

Milner has described the Prize as a public claim about value — about what a society decides deserves recognition and therefore resources. A researcher who spends forty years on a disease affecting a few thousand people, without a commercial path in sight, is making a bet that the science matters more than the return. The Prize says that bet was right. Baby KJ, walking and talking at a Hollywood ceremony that his existence helped explain, is what it looks like when that bet pays out.